Marie Curie Initial Training Network
About Celleurope


Contact Us


Celleurope Blog


Marie Curie Fellows

The project employs nine Early Career Researchers (in the first four years of their research career) and 3 Experienced Researchers (no more than four years work experience since gaining their PhD)

Early Career Researchers (ESR)

1.Rihab Gam, Newcastle University, United Kingdom Research Topic: Assessment of Molecular Biomarkers in Haematopoietic Stem Cell Transplantation

2. Pranali Shah, University Medical Centre Göttingen, Germany Research Topic: Predicting acute and chronic GvHD by gene expression profiling and testing of new targets

3. Dasaradha Jalapothu, University of Oslo, Norway Research Topic: Adaptive Repertoire Profiling a novel approach to predict GvHD

4. Mateja Kralj, Medical University Vienna, Austria Research Topic: Monitoring of GvHD and assessment of biomarkers for use post cellular therapy especially ECP

5. Sakhila Ghimire, University of Regensberg, Germany Research Topic: Monitoring Biology of GvHD using biomarkers and an investigation of epithelial inflammation in target tissues

6. Shuang Li, Charles University Prague, Czech Republic Research Topic: GvL effects of NK cells against human leukaemia cell lines - in vitro and in vivo studies

7. Margherita Boieri, University of Oslo, Norway Research Topic: Use of an animal model for studying GvHD/GVL and cellular therapies

8. Justyna Ogonek, Hannover Medical School, Germany Research Topic: Monitoring CMV reactivation and use of cellular therapy products (specific T cells) for CMV infection post HSCT

9. Monica Correia dos Reis, Newcastle University, United Kingdom Research Topic: Use of MSCs as a therapy for GvHD and regenerative medicine; investigation of mode of action and proliferative.

Experienced Researchers (ER).

The 3 ERs will mainly receive complementary skills training (e.g. project management, supervision of junior researchers, writing grant proposals)

1. Dr. Petra Mózes, Technical University Munich, Germany Research Topic: Determining soluble serum markers and membrane-bound NK ligands for the prediction of anti-tumour immune (GvL) responses and GvHD.

2. Dr. Marsela Qesari, Alcyomics Ltd, United Kingdom Research Topic: Comparative studies of the use of MSCs versus aptamers in GvHD responses using SkimuneTM, safety testing of CMV+ T cells and identification of targets by mRNA/miRNA analysis of GvH skin explants.

3. Dr. Michael Lutteropp, Miltenyi Biotech Gmbh, Germany Research Topic: Development of genetically modified T cells to target leukemic cells